B

BIOFORGE

Section 06

Business Model

Platform model: multiple revenue streams from quiz to concierge

TL;DR

BioForge makes money through a trust-first funnel. Free quiz builds a waitlist. $365 blood work (includes first consultation + protocol recommendation) has 50-70% margin and naturally funnels to peptide subscriptions. Peptide tiers at $299-999/month are the core revenue with 55-85% gross margins (wholesale peptide costs are shockingly low: BPC-157 = $18, CJC+Ipamorelin = $27, semaglutide = $21). Pre-filled pens justify premium pricing (2-3x over vials). People don't subscribe on day 1 — the trust journey is: Quiz -> Blood work -> First consultation -> First single peptide order -> Results -> THEN subscription. We don't build medical or pharmacy infrastructure — we partner with existing platforms (like Medvi did with CareValidate) and own the brand, the app, and the customer relationship. Website/app vibe-coded with AI at near-zero cost. $22K start, break-even by month 8-10.

Avg Revenue/Customer

$200/mo

Gross Margin (Y5)

72%

LTV:CAC

5.1x

Payback Period

1.75 mo

BioForge operates the Medvi-proven "thin layer" platform model but with ethics, compliance, and a better product. All regulated functions (medical consultations, prescriptions, compounding, fulfillment) are handled by licensed third-party partners. BioForge owns the brand, customer relationship, and AI-driven operations. The entire tech stack is vibe-coded with AI at near-zero cost. Gender-inclusive from day 1 (Hims started men-only then added Hers to reach $2.4B — we capture the full market immediately). Revenue comes from blood work funnel ($365 one-time), peptide subscriptions ($299-999/month core tiers), and premium plans ($5-50K/year in Year 2-3 roadmap). Pre-filled pens for specialty peptides are the key differentiator nobody else offers. Blood work is the imbuto (funnel) that leads to peptide subscriptions — not a standalone profit center.

Three-Entity Structure

1

BioForge (Dubai Free Zone LLC)

Technology & Marketing Layer

  • Brand identity and website (vibe-coded with AI, near-zero cost)
  • Quiz funnel + waitlist management
  • Customer acquisition (education-first content, paid media, SEO)
  • Checkout and payment processing
  • Customer service (AI chatbot + human escalation)
  • Data analytics and AI operations
  • Product strategy, pricing, and pre-filled pen partnerships

BioForge explicitly does not provide healthcare services and is not licensed to practice medicine. 0% corporate tax in Dubai free zone.

2

Telehealth Partner (e.g., CareValidate, OpenLoop, Wheel)

Clinical Infrastructure

  • Network of licensed US physicians (MD, DO, NP, PA)
  • Patient intake and medical review
  • Independent prescribing decisions
  • HIPAA-compliant data handling
  • State-by-state licensing compliance

Fee: estimated 40-50% of transaction value based on Medvi model.

3

Compounding Pharmacy Partners (503A/503B)

Pharmaceutical Fulfillment

  • Licensed compounding of prescription peptides
  • Pre-filled pen manufacturing (key differentiator)
  • Quality assurance and testing
  • Cold-chain packaging and shipping
  • FDA-registered facilities (503B)
  • State-licensed pharmacies (503A)

Cost: estimated 15-25% of transaction value for COGS. Pre-filled pen capability required for Longevity tier.

Unit Economics

Blood Work Funnel

$365 revenue, $100-180 cost (blood work $50-100 + telehealth $50-80) = 50-70% margin. Break-even or loss leader. The consultation tells you "here's what your numbers show, here's what I recommend" = the SOLUTION. Natural upsell to peptides.

Essential Tier

$299-399/month revenue, $45-80 cost (1 peptide wholesale + shipping) = 75-85% gross margin

Performance Tier

$499-699/month revenue, $120-200 cost (2-3 peptides + blood work + physician) = 65-75% gross margin

Longevity Tier

$799-999/month revenue, $250-400 cost (3-4 peptides + DNA + physician + pre-filled pens) = 55-65% gross margin

Blended Arpu

$400/month blended ARPU across paying subscribers

Cac

$350 target (vs. Medvi's $500-700) — lower due to education-first content + quiz funnel (40-60% lower CPA)

Ltv

$2,400 initially (6-month average retention at $400/mo) -> growing as trust journey increases retention

Ltv Cac Ratio

6.9x initially -> improving as organic growth and referrals reduce CAC

Payback Period

0.9 months (first month covers CAC for peptide subscribers)

Monthly Churn

15% Year 1 (trust still building), declining to 7% by Year 5 (protocol-driven retention after trust established)

Trust Journey

People don't subscribe day 1. Journey: Quiz -> Blood work ($365) -> First consultation -> First single peptide order (1 month, not subscription) -> See results -> THEN monthly subscription. Trust before subscription.

Revenue Streams

Peptide Subscriptions65%

Monthly peptide memberships ($299-999/mo) across Essential, Performance, and Longevity tiers — core revenue driver. Pre-filled pens in Longevity tier justify premium.

Blood Work Funnel15%

$365 one-time packages (blood work + first consultation + protocol recommendation). Cost $100-180. Funnel to peptides, not standalone profit center.

Single Peptide Orders12%

First-time single-month peptide orders (not subscriptions). Trust-building step before subscription. Converts at 40-60% to recurring subscription within 3 months.

Premium Plans (Year 2-3)5%

Concierge ($5-10K/yr) and Elite ($25-50K/yr) — in roadmap for Year 2-3, not at launch. Fewer customers, highest revenue per person.

Ancillary3%

Supplement recommendations, branded merchandise, referral bonuses.

Margin Evolution (5-Year)

2027: Year 1: $2-5M revenue. Compound reinvestment model — 100% gross profit back into ads. Break-even month 4-5. $1.9M total marketing spend.

2028: Year 2: $10-20M revenue. Volume discounts on pharmacy. Trust journey converts more subscribers.

2029: Year 3: $25-50M revenue. Direct pharmacy relationships. Pre-filled pen partnerships. Add concierge tiers.

2030: Year 4: $50-90M revenue. Negotiated platform rates, multi-market revenue, organic growth flywheel.

2031: Year 5: $80-150M revenue. Mature operations, potential vertical integration.

Scaling Strategy

Compound reinvestment bootstrap model: self-funded with $22K, reinvest 100% of gross profit into marketing. Payback period < 1 month means every dollar in ads returns $1.60+ in the same month. This is how Medvi reached $401M Y1 with $130-170M marketing spend. Phase 1 (Month 1-3): Build website/app (vibe-coded with AI). Quiz funnel + waitlist. Telehealth partner integration. 3 peptides (BPC-157, semaglutide, CJC-1295+Ipamorelin). Blood work at $365 as funnel. $5-9K/month ad spend compounding. Phase 2 (Month 4-6): Ad spend compounds to $14-38K/month from reinvested profits. 40-109 new customers/month. Break-even by month 4-5. Pre-filled pen partnerships. Phase 3 (Month 7-12): Exponential growth phase. Ad spend $63K-750K/month. Revenue hits $156K-1.85M/month. Year 1 total: $2-5M revenue. Phase 4 (Year 2-3): $10-50M revenue. Add concierge tiers ($5-10K/year). UAE market. Optional: raise $2-3M for own 503B pharmacy (COGS drops from 25% to 10%). Phase 5 (Year 4-5): $50-150M revenue. Add Elite tier ($25-50K/year). Multi-market. 20-25% net margin.